Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.
10.1007/s11596-015-1503-5
- Author:
Yu-juan TANG
1
;
Zai-zhong ZHANG
2
;
Shao-quan CHEN
2
;
Shu-ming CHEN
2
;
Cheng-jin LI
2
;
Jian-wei CHEN
2
;
Bo YUAN
2
;
Yin XIA
3
;
Lie WANG
4
Author Information
1. Department of General Surgery, Fuzhou General Hospital of Nanjing Command of PLA, Fuzhou, 350025, China. tangyujuan1234@163.com.
2. Department of General Surgery, Fuzhou General Hospital of Nanjing Command of PLA, Fuzhou, 350025, China.
3. Department of General Surgery, Fuzhou General Hospital of Nanjing Command of PLA, Fuzhou, 350025, China. xiayin1118@163.com.
4. Department of General Surgery, Fuzhou General Hospital of Nanjing Command of PLA, Fuzhou, 350025, China. fzptwk@126.com.
- Publication Type:Journal Article
- Keywords:
angiotensin II;
infantile hemangiomas;
propranolol gel;
renin;
vascular endothelial growth factor
- MeSH:
Administration, Cutaneous;
Adrenergic beta-Antagonists;
therapeutic use;
Angiotensin II;
blood;
Case-Control Studies;
Female;
Gels;
Hemangioma, Capillary;
blood;
blood supply;
drug therapy;
pathology;
Humans;
Infant;
Infant, Newborn;
Male;
Propranolol;
therapeutic use;
Renin;
blood;
Skin Neoplasms;
blood;
blood supply;
drug therapy;
pathology;
Treatment Outcome;
Vascular Endothelial Growth Factor A;
blood
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(5):759-762
- CountryChina
- Language:English
-
Abstract:
The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated. Thirty-three consecutive children with superficial IHs were observed pre-treatment, 1 and 3 months after application of topical propranolol gel for the levels of plasma renin, ATII and VEGF in Department of General Surgery of Dongfang Hospital from February 2013 to February 2014. The plasma results of IHs were compared with those of 30 healthy infants of the same age from out-patient department. The clinical efficiency of topical propranolol gel at 1st, and 3rd month after application was 45%, and 82% respectively. The levels of plasma renin, ATII and VEGF in patients pre-treatment were higher than those in healthy infants (565.86 ± 49.66 vs. 18.19 ± 3.56, 3.20 ± 0.39 vs 0.30 ± 0.03, and 362.16 ± 27.29 vs. 85.63 ± 8.14, P < 0.05). The concentrations of VEGF and renin at 1st and 3rd month after treatment were decreased obviously as compared with those pre-treatment (271.51 ± 18.59 vs. 362.16 ± 27.29, and 405.18 ± 42.52 vs. 565.86 ± 49.66 P < 0.05; 240.80 ± 19.89 vs. 362.16 ± 27.29, and 325.90 ± 35.78 vs. 565.86 ± 49.66, P < 0.05, respectively), but the levels of plasma ATII declined slightly (2.96 ± 0.37 vs. 3.20 ± 0.39, and 2.47 ± 0.27 vs. 3.20 ± 0.39, P > 0.05). It was indicated that the increased renin, ATII and VEGF might play a role in the onset or development of IHs. Propranolol gel may suppress the proliferation of IHs by reducing VEGF.
